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Introduction: Long-term left ventricular assist devices are nowadays part of standard therapy
for patients in terminal phase of heart failure. Lower invasiveness of implantation might
have the potential to enhance results of these high risk patients. The aim of this study is to
introduce our minimally invasive approach to the implantation of left ventricular assist
device of the latest generation HeartWare ventricle assist device (HVAD) and our initial
experience with this method.
Methods: In our department we implanted HVAD between November 2013 and November
2014 in 8 patients as a bridge to heart transplantation. All patients were male with average
age 59.5  6.4 years. Basic diseases were dilated cardiomyopathy in 6 patients (75%), ische-
mic cardiomyopathy in 2 patients (25%). The mean value of left ventricular ejection fraction
was 10  3.6%, right ventricular ejection fraction was 35  5.6%. Access to the left ventricular
apex was reached by left-sided thoracotomy of approximately 8 cm. To access the ascending
aorta we used upper J ministernotomy.
Results: Minimally invasive implantation was successfully done in all patients. In one
patient closure of foramen ovale was simultaneously performed. Most patients (75%) were
extubated on the ﬁrst postoperative day. In one case, a failure of the right ventricle occurred
with the need for temporary right-sided circulatory support device Centrimag. No patient
died, four patients have successfully undergone heart transplantation, other are followed on
an outpatient basis.
Conclusion: Minimally invasive implantation of left ventricular assist device HeartWare
HVAD is safely feasible. After a very good initial experience with this technique it has
become the method of choice in our department.
# 2015 The Czech Society of Cardiology. Published by Elsevier Sp. z o.o. All rights
reserved.
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Implantation of left ventricular assist device (LVAD) as a
bridge to heart transplantation nowadays represents part
of standard therapy for the group of critically ill patients
in the Czech Republic [1,2]. Guidelines of European Society
of Cardiology recommend LVAD implantation in patients
awaiting heart transplantation to improve their symptoms
and to prevent readmission due to worsened heart failure
(Class I/B recommendation) [3].
Standard medial sternotomy is the most frequent
approach for LVAD implantation worldwide. Substitution
of full sternotomy with smaller incisions may lead to the
same effects as other minimally invasive cardiac surgery,
i.e. to reduce blood loss, number of blood transfusions,
infections, time of mechanical ventilation, length of ICU
stay and total time of hospitalization [4,5]. These approaches
are particularly beneﬁcial for polymorbid and elderly
patients [6]. A further positive factor of great signiﬁcance
is that the minimally invasive approach does not disrupt
the integrity of pericardium, and thus we can avoid the
negative impact of pericardium opening on the function of
the right ventricle [7–9]. This approach left the sternum
largely intact and outﬂow graft of LVAD is covered by
pericardium, which considerably simpliﬁes subsequent
heart transplantation.
HeartWare VAD (HVAD) represents the latest LVAD
generation of substantially smaller dimensions comparing
to preceding systems, which enables completely intraperi-
cardial implantation (see Fig. 1).
To perform minimally invasive HVAD implantation we
apply incisions which have been commonly used in our
department to perform other operations. Thus, we managed
to eliminate the potential effect of learning curves. We
use left-sided minithoracotomy to perform transapical
transcatheter aortic valve implantation. The upper partial
J ministernotomy is used for minimally invasive aortic
valve replacement.Fig. 1 – Miniaturized centrifugal pump HeartWare with
integrated inflow cannula. Material and methods
Group of patients
In our department, the implantation of mechanical circulatory
support has been carried out since 2009; we have performed
57 operations in total. Since February 2013, we have implanted
HVAD as a bridge to heart transplantation in 11 patients in
total, 8 of whom, who are the subject to this study, underwent
the minimally invasive approach. All patients were male, the
median age of the patients was 59.5  6.4 years. Six patients
suffered from dilated cardiomyopathy (75%), ischemic cardio-
myopathy was the primary disease in 2 patients (25%). The
mean left ventricular ejection fraction was 10  3.6%, right
ventricular ejection fraction was 35  5.6%, diastolic diameter
of the right ventricle (RV) was 42  5.2 mm. TAPSE (tricuspid
annular plane systolic excursion) was 17  3.5 mm. Other
diseases included diabetes in 4 patients (50%), chronic
obstructive pulmonary disease in 4 patients (50%), chronic
renal insufﬁciency in 2 patients (25%), hepatopathy in
3 patients (37.5%).
HeartWare HVAD
The system of implantable left ventricular assist device HVAD
consists of a miniaturized centrifugal pump with integrated
inﬂow cannula and outﬂow graft, external control unit and
an external source of energy (2 batteries, power supply)
(see Fig. 2). The pump is attached to the left ventricular apexFig. 2 – HeartWare HVAD.
Fig. 3 – Surgical approach: left-sided minithoracotomy and
upper ministernotomy.
Fig. 5 – Implanted HeartWare HVAD.
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anastomosed to the side of ascending aorta.
Implantation
The left ventricular apex is reached by left-side thoracotomy of
approximately 8 cm in the fourth or ﬁfth intercostal space. For
precise detection of left ventricular (LV) apex the transthoracic
echocardiography was used immediately before operation.
Simultaneously J-shaped upper ministernotomy was per-
formed. The sternum from was opened from the jugulum to
the 3rd or 4th intercostal space to the right (see Fig. 3). After
the pericardium is opened above both the apex and the aorta,
the cannulation and extracorporeal circulation take place.
Arterial cannula is inserted into the ascending aorta. Venous
cannula is inserted via the femoral vein in the right groin into
the right atrium. By means of transesophageal echocardiogra-
phy we determine by pressure of the ﬁnger on LV apex an
ideal place for the pump implantation. In the proper spot
the implantation ring is sutured to myocardium (Fig. 4).Fig. 4 – Implantation ring sutured to left ventricular apex.Cardiopulmonary bypass is set off. Further steps are as follows:
opening of the left ventricle by a cylindrical knife, left ventricular
cavity inspection and connection of the pump (Fig. 5). The
outﬂow graft is pulled intrapericardially and its end is sutured to
the side of ascending aorta (Fig. 6). When de-airing of the system
is completed, the support gradually starts up. We always make
the effort to close the pericardium by direct suture. Alternatively
HVAD is overlapped by CorMatrix membrane.
Results
Minimally invasive implantation was successful in all
patients. In one patient closure of foramen ovale was
simultaneously performed. Most of the patients (75%) were
extubated on the ﬁrst postoperative day. Reoperation due to
post-operative bleeding was necessary in two patients. In
one case a feared failure of right ventricle occurred with the
need for temporary right-sided mechanical supports withFig. 6 – Anastomosis of the outflow graft to the side of
ascending aorta.
Table 1 – Results (n = 8).
Cardiopulmonary bypass (min) 63.5  25.4
Erythrocytes (transf. units) 2.5  6.1
Thrombocytes (transf. units) 2  2.8
Frozen plasma (transf. units) 6.5  8.5
Mechanical ventilation (days) 1  2.95
ICU stay (days) 11.5  5.29
Hospital admission (days) 26  7.30
Bleeding with the need of reoperation 1 (12.5%)
RV mechanical support 1 (12.5%)
Cerebrovascular accident 0 (0%)
Mortality 0 (0%)
Quantitative ﬁgures are given as a median value and standard
deviation.
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ously. No patient from our group died. Four patients have
already successfully undergone heart transplantation. De-
tailed results are given in Table 1.
Discussion
The use of a long-term LVAD has signiﬁcantly expanded the
treatment options of patients in terminal stage of heart failure.
LVAD implantation is however still burdened with signiﬁcant
perioperative and post-operative morbidity and mortality.
Among the complications the most feared are: right ventricu-
lar failure, bleeding and complications connected with long-
term mechanical ventilation.
Perioperative failure of the right ventricle is connected with
high rate of early morbidity and mortality and its prediction
still remains difﬁcult [10]. Our method of approaching the left
ventricular apex through the left-minithoracotomy maintains
the integrity of pericardium above the RV, thereby signiﬁcantly
reducing the risk of the RV dilatation [7–9]. In comparison to
the traditional approach, the manipulation of the heart is
minimized, which reduces the risk of arrhythmias [8]. Both of
these factors contribute the lower frequency of RV failure.
Thus only one signiﬁcant postoperative RV failure necessitat-
ing 19 days of temporary RV support occurred in our group of
patients.
The described approach signiﬁcantly reduces surgical
trauma and thus, there is no need for greater mediastinal
dissection. Our group was too small to enable a comparison
with the classical approach, nevertheless we can conﬁrm the
tendency to lower blood loss described by other authors
[8,9,11].
Prolonged mechanical ventilation is a factor that has a very
strong relation to mortality in cardiac surgery [12]. Minimally
invasive implantation maintains the continuity at the bottom
of the thoracic cage and the diaphragm is also not affected
during the operation. It contributes to the possibility to
extubate most patients (75%) during the ﬁrst postoperative
day, which is, in case of LVAD implantation, a very encourag-
ing result.
In our group LVAD implantation was indicated as a bridge
to heart transplantation, which has been successfully per-
formed in 4 patients. From a surgical point of view we
appreciated the largely intact sternum, the outﬂow graftcovered by pericardium and lower tendency to adhesions in
the pericardial cavity which made subsequent cardiac trans-
plantation much easier.
It is vital to mention the drawbacks of a minimally invasive
approach. Direct access to the left ventricular apex might be
technically demanding due to small thoracotomy. It has been
proved to be beneﬁcial when surgeon identiﬁes the apex
position by transthoracic echocardiography immediately prior
to surgery. Upper ministernotomy brings limited access to
the ascending aorta and consequent dealing with possible
complications connected with anastomosis of outﬂow graft
may be technically challenging as well. In comparison with the
classical approach the inspection of the outﬂow graft course is
more difﬁcult, particularly when malrotation is concerned.
Each new surgical procedure carries the risk of learning
curves. This phenomenon was meaningfully reduced in our
situation, because both miniinvasive approaches are com-
monly used in our department to carry out other operations.
Upper ministernotomy is regularly used for aortic valve
replacement and left-minithoracotomy for transapical trans-
catheter aortic valve implantation.
Conclusion
Minimally invasive implantation of HeartWare HVAD is safely
feasible. After very good initial experience with this technique
it has become the method of choice in our department.
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